CM380 / Keymed Biosciences - LARVOL DELTA

Keymed Biosciences Announces Annual Results of 2024 (GlobeNewswire) - "CM380 (GPRC5D×CD3 bispecific antibody): As of the date of this announcement, we are planning to conduct a multi-center, open-label Phase I/II clinical study for evaluation of CM380 in treatment of patients with relapsed or refractory multiple myeloma."

New P1/2 trial • Multiple Myeloma

Keymed Biosciences Announces Interim Results for First Half of 2024 (PRNewswire) - "Keymed Biosciences Inc...announced its interim results for the first half of 2024, along with a corporate update....Submitted IND application, and planned to conduct a multi-center, open-label Phase I/II clinical study for evaluation of CM380 in treatment of patients with relapsed or refractory multiple myeloma."

IND • Hematological Malignancies • Multiple Myeloma • Oncology